A citation-based method for searching scientific literature

Katrin M Sjoquist, David Espinoza, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Sonia Yip, Jeffrey Goh, David Bowtell, Michelle Harrison, Michael L Friedlander. Gynecol Oncol 2021
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tumor evolution and chemoresistance in ovarian cancer.
Soochi Kim, Youngjin Han, Se Ik Kim, Hee-Seung Kim, Seong Jin Kim, Yong Sang Song. NPJ Precis Oncol 2018
53
100


Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
Robert E Bristow, Rafael S Tomacruz, Deborah K Armstrong, Edward L Trimble, F J Montz. J Clin Oncol 2002
50

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
50

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
Alexi A Wright, Angel Cronin, Dana E Milne, Michael A Bookman, Robert A Burger, David E Cohn, Mihaela C Cristea, Jennifer J Griggs, Nancy L Keating, Charles F Levenback,[...]. J Clin Oncol 2015
103
50

Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1).
Muhammad Wasif Saif, Andrew Heaton, Kimberley Lilischkis, James Garner, David M Brown. Cancer Chemother Pharmacol 2017
5
50

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
D S Alberts, P Y Liu, E V Hannigan, R O'Toole, S D Williams, J A Young, E W Franklin, D L Clarke-Pearson, V K Malviya, B DuBeshter. N Engl J Med 1996
875
50

Stem cells, cancer, and cancer stem cells.
T Reya, S J Morrison, M F Clarke, I L Weissman. Nature 2001
50

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Deborah K Armstrong, Brian Bundy, Lari Wenzel, Helen Q Huang, Rebecca Baergen, Shashikant Lele, Larry J Copeland, Joan L Walker, Robert A Burger. N Engl J Med 2006
50

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
Chad A Hamilton, G Larry Maxwell, Mildred R Chernofsky, Sarah A Bernstein, John H Farley, G Scott Rose. Gynecol Oncol 2008
62
50

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
135
50

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M Oza,[...]. Lancet Oncol 2019
142
50


Cancer of the ovary, fallopian tube, and peritoneum.
Jonathan S Berek, Christopher Crum, Michael Friedlander. Int J Gynaecol Obstet 2015
47
50

Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo.
Alexander J Stevenson, Eleanor I Ager, Martina A Proctor, Dubravka Škalamera, Andrew Heaton, David Brown, Brian G Gabrielli. Sci Rep 2018
3
50

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Charles N Landen, Blake Goodman, Ashwini A Katre, Adam D Steg, Alpa M Nick, Rebecca L Stone, Lance D Miller, Pablo Vivas Mejia, Nicolas B Jennings, David M Gershenson,[...]. Mol Cancer Ther 2010
255
50

A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients.
Caitlin Phillips-Chavez, Michael Watson, Jermaine Coward, Janet Schloss. Eur J Clin Pharmacol 2020
4
50

Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.
Shannon M McAuliffe, Stefanie L Morgan, Gregory A Wyant, Lieu T Tran, Katherine W Muto, Yu Sarah Chen, Kenneth T Chin, Justin C Partridge, Barish B Poole, Kuang-Hung Cheng,[...]. Proc Natl Acad Sci U S A 2012
222
50

Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
Wei-Chun Chen, Jiantai Timothy Qiu, Chyong-Huey Lai, Huei-Jean Huang, Cheng-Tao Lin, Min-Yu Chen, Hung-Hsueh Chou, Kuan-Gen Huang, Ting-Chang Chang. PLoS One 2017
3
50

A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer.
Siddik Sarkar, Obeid M Malekshah, Alireza Nomani, Niket Patel, Arash Hatefi. Cancer Med 2018
5
50

Prognostic value of radiological recurrence patterns in ovarian cancer.
Joline F Roze, Wouter B Veldhuis, Jacob P Hoogendam, René H M Verheijen, Rob J P M Scholten, Ronald P Zweemer. Gynecol Oncol 2020
3
50

Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Amelia M Huehls, Jill M Wagner, Catherine J Huntoon, Liyi Geng, Charles Erlichman, Anand G Patel, Scott H Kaufmann, Larry M Karnitz. Cancer Res 2011
33
50



Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs.
Dan-Arin Silasi, Ayesha B Alvero, Thomas J Rutherford, David Brown, Gil Mor. Expert Opin Pharmacother 2009
32
50

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Susan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer,[...]. Gynecol Oncol 2016
144
50

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B Olawaiye, Susan L Ellard, Johanne I Weberpals, Andrea E Wahner Hendrickson,[...]. Lancet 2021
16
50


Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence.
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Makio Shozu. Int J Clin Oncol 2020
3
50

Improved early detection of ovarian cancer using longitudinal multimarker models.
Harry J Whitwell, Jenny Worthington, Oleg Blyuss, Aleksandra Gentry-Maharaj, Andy Ryan, Richard Gunu, Jatinderpal Kalsi, Usha Menon, Ian Jacobs, Alexey Zaikin,[...]. Br J Cancer 2020
17
50


Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2.
Qiaohua Peng, Jiale Qin, Yanan Zhang, Xiaodong Cheng, Xinyu Wang, Weiguo Lu, Xing Xie, Songfa Zhang. J Exp Clin Cancer Res 2017
37
50

Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Michael G Kelly, Gil Mor, Alan Husband, David M O'Malley, Lisa Baker, Masoud Azodi, Peter E Schwartz, Thomas J Rutherford. Int J Gynecol Cancer 2011
25
50

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.
Filippo Bellati, Chiara Napoletano, Ilary Ruscito, Maria Pastore, Milena Pernice, Morena Antonilli, Marianna Nuti, Pierluigi Benedetti Panici. Invest New Drugs 2010
34
50

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
Jianqun Liao, Feng Qian, Nana Tchabo, Paulette Mhawech-Fauceglia, Amy Beck, Zikun Qian, Xinhui Wang, Wendy J Huss, Shashikant B Lele, Carl D Morrison,[...]. PLoS One 2014
207
50

Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
Giovanni D Aletti, Karl C Podratz, William A Cliby, Bobbie S Gostout. Gynecol Oncol 2009
31
50

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.
Ardian Latifi, Rodney B Luwor, Maree Bilandzic, Simon Nazaretian, Kaye Stenvers, Jan Pyman, Hongjian Zhu, Erik W Thompson, Michael A Quinn, Jock K Findlay,[...]. PLoS One 2012
133
50

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
Lisa M Landrum, James Java, Cara A Mathews, Grainger S Lanneau, Larry J Copeland, Deborah K Armstrong, Joan L Walker. Gynecol Oncol 2013
84
50

Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer.
Kimberly Kanigel Winner, Mara P Steinkamp, Rebecca J Lee, Maciej Swat, Carolyn Y Muller, Melanie E Moses, Yi Jiang, Bridget S Wilson. Cancer Res 2016
19
50


TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo.
Ayesha B Alvero, Andrew Heaton, Eydis Lima, Mary Pitruzzello, Natalia Sumi, Yang Yang-Hartwich, Carlos Cardenas, Sahra Steinmacher, Dan-Arin Silasi, David Brown,[...]. Mol Cancer Ther 2016
12
50

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets.
Chiara Napoletano, Ilary Ruscito, Filippo Bellati, Ilaria Grazia Zizzari, Hassan Rahimi, Maria Luisa Gasparri, Morena Antonilli, Pierluigi Benedetti Panici, Aurelia Rughetti, Marianna Nuti. J Clin Med 2019
12
50


Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, Eric Pujade-Lauraine, Michael Quinn, Tate Thigpen, Andreas du Bois, Gunnar Kristensen, Anders Jakobsen, Satoru Sagae,[...]. Int J Gynecol Cancer 2011
351
50

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Danielle A Jandial, William E Brady, Stephen B Howell, Heather A Lankes, Russell J Schilder, Jan H Beumer, Susan M Christner, Sandra Strychor, Matthew A Powell, Andrea R Hagemann,[...]. Gynecol Oncol 2017
12
50

Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
Danielle D Jandial, Salman Farshchi-Heydari, Christopher A Larson, Gregory I Elliott, Wolfgang J Wrasidlo, Stephen B Howell. Clin Cancer Res 2009
71
50

Integrative analysis of transcription factors and microRNAs in ovarian cancer cell spheroids.
Hyun Park, Sohyun Hwang, Ju-Yeon Jeong, Sang Geun Jung, Min Chul Choi, Won Duk Joo, Seung Hun Song, Chan Lee, Hee Jung An. J Ovarian Res 2020
5
50

New perspectives on targeted therapy in ovarian cancer.
Jermaine Ig Coward, Kathryn Middleton, Felicity Murphy. Int J Womens Health 2015
73
50

Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
Patrycja Tudrej, Magdalena Olbryt, Ewa Zembala-Nożyńska, Katarzyna A Kujawa, Alexander J Cortez, Anna Fiszer-Kierzkowska, Wojciech Pigłowski, Barbara Nikiel, Magdalena Głowala-Kosińska, Aleksandra Bartkowska-Chrobok,[...]. Int J Mol Sci 2018
10
50

Molecular mechanisms of drug resistance in ovarian cancer.
Leyla Norouzi-Barough, Mohammad Reza Sarookhani, Mohammadreza Sharifi, Sahar Moghbelinejad, Saranaz Jangjoo, Rasoul Salehi. J Cell Physiol 2018
73
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.